Literature DB >> 32234821

Clinical Reasoning: A 16-year-old girl with ataxia, oscillopsia, and behavioral changes.

Andrew Silverman1, Chindhuri Selvadurai2, John Picard2, Lauren Gluck2, Adeniyi Fisayo2, Naila Makhani2, Viviana Benitez2.   

Abstract

Entities:  

Year:  2020        PMID: 32234821      PMCID: PMC7282879          DOI: 10.1212/WNL.0000000000009297

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  10 in total

1.  Key role of CXCL13/CXCR5 axis for cerebrospinal fluid B cell recruitment in pediatric OMS.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Anna L Travelstead; Richard M Ransohoff; Jayne M Ness; Jerry A Colliver
Journal:  J Neuroimmunol       Date:  2012-01-20       Impact factor: 3.478

2.  Treatment responsive opsoclonus-ataxia associated with ovarian teratoma.

Authors:  I Kawachi; E Saji; Y Toyoshima; J Dalmau; M Nishizawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-05       Impact factor: 10.154

3.  Opsoclonus-myoclonus syndrome associated with benign ovarian teratoma.

Authors:  A S Fitzpatrick; O M Gray; J McConville; G V McDonnell
Journal:  Neurology       Date:  2008-04-08       Impact factor: 9.910

4.  Myoclonic encephalopathy of infants.

Authors:  M Kinsbourne
Journal:  J Neurol Neurosurg Psychiatry       Date:  1962-08       Impact factor: 10.154

Review 5.  Saccadic intrusions: review and update.

Authors:  João Lemos; Eric Eggenberger
Journal:  Curr Opin Neurol       Date:  2013-02       Impact factor: 5.710

6.  A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma.

Authors:  Thaís Armangue; Maarten J Titulaer; Lidia Sabater; Javier Pardo-Moreno; Nuria Gresa-Arribas; Natalia Barbero-Bordallo; Gordon R Kelley; Noh Kyung-Ha; Akitoshi Takeda; Takahiro Nagao; Yukitoshi Takahashi; Angélica Lizcano; Aisling S Carr; Francesc Graus; Josep Dalmau
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

7.  Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.

Authors:  Michael R Pranzatelli; Elizabeth D Tate; Nathan R McGee; Craig A MacArthur
Journal:  Pediatr Neurol       Date:  2018-05-18       Impact factor: 3.372

8.  Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma.

Authors:  Emil Lou; Martee L Hensley; Andrew B Lassman; Carol Aghajanian
Journal:  Gynecol Oncol       Date:  2010-02-07       Impact factor: 5.482

9.  Opsoclonus-ataxia syndrome associated with ovarian mature teratoma.

Authors:  Kiyoshi Kanno; Syogo Kin; Masaki Hirose; Satoshi Suzuki; Takafumi Watanabe; Keiya Fujimori
Journal:  J Obstet Gynaecol Res       Date:  2015-03-15       Impact factor: 1.730

10.  NMDA receptor antibody in teratoma-related opsoclonus-myoclonus syndrome.

Authors:  Nicolás X Urriola; Jacob Helou; Joel Maamary; Jacob Pogson; Frederick Lee; Kaitlyn Parratt; David Gillis; Michael J Fulham; G Michael Halmágyi
Journal:  J Clin Neurosci       Date:  2018-10-16       Impact factor: 1.961

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.